Chemotherapy: The suggested phase II dose for weekly Taxotere with concomitant standard chest radiotherapy was determined to be 20mg/m2. In our unpublished phase I clinical trial, we found 35 mg/m2 to be well tolerated and therefore this dose is chosen for this phase II study. The drug will be administered intravenously on the same day as the radiation. All patients will be premedicated 12 hours prior to chemotherapy with Decadrone. Patients will be followed and evaluated weekly by a physician.